Previous Chapter Chapter 29: Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth Next Chapter

By: Decision Resources Inc

In: The SAGE Handbook of Healthcare

Chapter 29: Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth

  • Citations
  • Add to My List
  • Text Size

Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth
Chronic lymphocytic leukemia: Monoclonal antibodies will drive steady growth
Introduction

Chronic lymphocytic leukemia (CLL), which is considered incurable, is the most common leukemia in the Western world. Current research is focusing on the urgent unmet need for agents that improve survival, particularly for patients with advanced disease. Improved responses from treatment regimens that combine targeted biological agents with established chemotherapy, as well as increased drug therapy for early-stage patients who are likely to progress based on potential prognostic markers, have already begun and will continue to create market opportunities and propel steady growth of the CLL market.

In this chapter, we provide an overview of CLL, including its staging, epidemiology, and biological markers. We focus on the US market ...

Looks like you do not have access to this content.

Login

Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website